The combination of encorafenib plus binimetinib significantly improved overall survival versus vemurafenib in patients with BRAF-mutant melanoma, updated results of the randomized, phase three COLUMBUS trial show.
Andrew D. Bowser
Advertisement
Articles by Andrew D. Bowser
Researchers reporting at the American Society of Clinical Oncology annual meeting on June 4 presented a study in which they compared the seventh and eighth editions of the American Joint Committee on Cancer melanoma staging systems. The eighth edition differentiates melanoma survival slightly worse than the previous edition.
Pembrolizumab has antitumor activity that is durable long after treatment is stopped in patients with advanced melanoma, researchers reported at the 2018 annual meeting of the American Society of Clinical Oncology (ASCO) on June 4.
Advertisement
Latest Updated Articles
- Immunotherapy still works post treatment in melanoma
Published: June 11th 2018 | Updated:
- It may be time to update the melanoma staging system, researchers report
Published: June 11th 2018 | Updated:
- Combination therapy improves survival in melanoma
Published: June 11th 2018 | Updated:
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
4
Dermatology Conferences and Meetings Calendar: December 2025
5
